Tenofovir
From Biocrawler, the free encyclopedia.
Tenofovir disoproxil fumarate (TDF) belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (NtRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV-infected people. It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. This indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts in controlled studies of tenofovir in treatment-naïve and treatment-experienced adults. There are no study results demonstrating the effect of tenofovir on clinical progression of HIV.
Tenofovir is currently in late-stage clinical trials for the treatment of hepatitis B.
Tenofovir is marketed by Gilead Sciences with the brand name Viread. It was approved by the U.S. Food and Drug Administration (FDA) on July 2, 2003. It is also available combined with emtricitabine in a product with the brand name Truvada, approved on August 2, 2004 for once-a-day dosing.
 | This medical treatment article is a stub. You can help Biocrawler by expanding it (http://www.biocrawler.com/w/index.php?title=Tenofovir&action=edit). |
